文献速递炎症性肠病

挂线对接受抗TNF治疗的克罗恩病肛瘘患者结局的影响:一项多中心研究

The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Multicentre Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-03-18

该多中心研究纳入2005至2022年间6个北美中心首次接受抗TNF治疗的肛瘘型克罗恩病患者221例(挂线组81例,无挂线组140例),采用1:1基数匹配和倾向评分加权控制瘘管严重程度。挂线组与无挂线组的主要不良瘘管结局(HR 1.23;95%CI 0.68-2.21)及6个月(OR 0.81;95%CI 0.41-1.59)和12个月(OR 0.63;95%CI 0.31-1.27)临床瘘管缓解率均相似。结论认为挂线未与改善瘘管结局相关,需未来前瞻性对照研究。

要点

  • 挂线组与无挂线组主要不良瘘管结局风险相似(HR 1.23;95%CI 0.68-2.21)。
  • 6个月和12个月临床瘘管缓解率在两组间相似(OR分别为0.81和0.63)。
  • 合并脓肿患者中挂线组主要不良瘘管结局发生率较低(HR 0.49;95%CI 0.19-1.25),但未达统计学显著。

核心结论

  • 在这项多中心研究中,挂线未与改善瘘管结局相关。
  • 未来需开展前瞻性对照研究。

研究设计与样本

  • 多中心研究,纳入2005至2022年间6个北美中心首次接受抗TNF治疗的肛瘘型克罗恩病患者。
  • 暴露为抗TNF治疗时存在一个或多个挂线。
  • 共纳入221例患者:挂线组81例,无挂线组140例。
  • 采用1:1基数匹配和倾向评分加权控制瘘管严重程度(基于中心判读的MRI、腔道特征和合并治疗)。

主要发现

  • 基数匹配后队列均衡(所有协变量标准化差异<0.1)。
  • 挂线组与无挂线组主要不良瘘管结局发生率相似(HR 1.23;95%CI 0.68-2.21)。
  • 挂线组与无挂线组6个月临床瘘管缓解率相似(OR 0.81;95%CI 0.41-1.59)。
  • 挂线组与无挂线组12个月临床瘘管缓解率相似(OR 0.63;95%CI 0.31-1.27)。
  • 倾向评分加权分析和麻醉下检查患者的敏感性分析结果稳定;合并脓肿患者中挂线组主要不良瘘管结局发生率较低(HR 0.49;95%CI 0.19-1.25),但未达统计学显著。

关键数值与推荐

  • 主要结局为主要不良瘘管结局(MAFO),由重复局部手术干预、住院或为肛瘘型克罗恩病行粪便转流组成的复合终点。
  • 次要结局为临床定义的瘘管缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需开展前瞻性对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We aimed to assess the impact of setons on perianal fistula outcomes in patients with perianal fistulising Crohn's disease (PFCD) treated with anti-TNF therapy. METHODS: We included patients treated with their first anti-TNF therapy for PFCD after undergoing a pelvic MRI between 2005 and 2022 from 6 North American centres. Our exposure was one or more setons at the time of anti-TNF therapy. Our primary outcome was major adverse fistula outcome (MAFO), a composite of repeat local surgical intervention, hospitalisation, or faecal diversion for PFCD, and our secondary outcome was fistula remission defined clinically. We used 1:1 cardinality matching and propensity score weighting to control for fistula severity based on centrally read MRIs, luminal characteristics, and concomitant therapies. RESULTS: Our analysis included 221 patients: 81 with setons and 140 without setons. After cardinality matching, our cohorts were balanced (standardised difference < 0.1 for all covariates). Patients with setons had similar rates of MAFO (HR 1.23; 95% CI, 0.68-2.21) and fistula remission at 6 months (OR, 0.81; 95% CI, 0.41-1.59) and 12 months (OR, 0.63; 95% CI, 0.31-1.27) compared to patients without setons. Our results remained stable when analysed by propensity score weighting and in a sensitivity analysis of patients who underwent an exam under anaesthesia. In patients with abscesses, there were lower rates of MAFO (HR, 0.49; 95% CI, 0.19-1.25) but not statistically significant in patients with setons. CONCLUSIONS: In this multicentre, setons were not associated with improved fistula outcomes. Future prospective controlled studies are warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. McCurdy J, Munir J, Parlow S, et al. The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Multicentre Study. Aliment Pharmacol Ther. 2025. PMID: 40098436. doi:10.1111/apt.70081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。